UBS analyst Paul Gong initiated coverage of XPeng’s Hong Kong-listed shares with a Neutral rating and a price target of HK$47.00, citing robotics value already priced in and a car business weighed down by competition and weak margins.
Gong’s valuation rests on a sum-of-the-parts framework with 30% of the value derived from robotics — an unusually large share for a business that has yet to generate revenue.
“XPeng is arguably one of the most active robot players among Chinese carmakers, and has successfully crystallised US$4.3bn of value through its robotics financing,” Gong wrote in a new note published on Wednesday.
The analyst acknowledged the robot opportunity while simultaneously warning that the core auto segment is dragging on the investment case — two weeks after the company reported weaker than expected second-quarter financial results.
Based on Wednesday’s closing price of HK$42.30, the price target implies about 11.1% upside.
Shares are trading near the bottom of their 52-week range of HK$41.60 to HK$110.80 and have fallen about 71.8% from their November 2021 peak of HK$206.20.
The one-year consensus target among analysts covering the stock sits at HK$77.68 — 65.3% above UBS’s figure and nearly double the current price.
The Robotics Case
UBS noted that “through external investors, the robotics business is now valued at US$6.3bn” and that XPeng “retains a 68.4% stake, crystallising US$4.3bn of value in the listed company.”
XPeng’s robotics subsidiary Dogotix raised more than $900 million in late August at a post-money valuation above $6.3 billion, led by IDG Capital with Gaorong Ventures and strategic backing from Tencent and Alibaba.
Gong acknowledged that “management aims to mass produce robots by end-2026 and deploy them in shops as shopping assistants.”
XPeng commissioned its IRON humanoid robot production lines in Guangzhou on September 8 and said the first unit walked off the line under its own power.
Founder and CEO He Xiaopeng called the moment “small” while holding to the year-end mass production target.
UBS was less certain the timeline translates into returns.
“Humanoid robotics is a new battleground with about 160 full-stack humanoid robot developers and many component suppliers,” the analyst stated, adding that “the journey towards mass commercialisation and monetisation still looks long and uncertain.”
The analyst pointed to limited evidence of capability beyond basic locomotion.
He warned that “so far, XPeng’s robot has demonstrated lower limb motion control in catwalk demonstrations,” stating that “whether this will translate into commercial success remains to be seen.”
Dogotix’s own accounts, disclosed for the first time in its HKEX filing, showed net liabilities of about 447 million yuan ($66.6 million) as of March 31 and losses that quadrupled from 87 million yuan in 2024 to 369 million yuan in 2025.
Investors hold a redemption right that could require XPeng to buy back $600 million of shares with 8% compound interest if Dogotix fails to complete an IPO within seven years.
Car Business Under Pressure
According to Paul Gong, XPeng’s car business “still faces challenges from intense competition, supply chain and short shelf lives, which led to a weaker financial performance than the market expected.”
XPeng reported second-quarter revenue of 19.74 billion yuan ($2.9 billion), missing analysts’ average estimate of 20.57 billion yuan ($3.1 billion).
Net losses nearly tripled year on year to 1.34 billion yuan ($200 million).
Vehicle margin fell to 12.1% from 14.3%, with services contributing 49.6% of gross profit on just 13.7% of revenue.
Third-quarter guidance of 21.7 billion to 23.4 billion yuan landed about 15% below the LSEG consensus of 26.61 billion yuan, prompting four analysts to cut their price targets while mostly retaining Buy ratings.
US-listed shares plunged more than 7% on August 24 after the results, extending a decline that had already pushed XPeng to a 19-month low of $11.49 on August 13 as BlackRock cut its position by 23.5%.
Hong Kong-listed shares have continued to weaken through September, trading as low as HK$41.60 — matching the 52-week floor.
Where UBS Sits Among Peers
UBS’s Neutral rating and HK$47 target make it the most cautious initiation among major brokerages covering XPeng’s Hong Kong listing.
Barclays holds the only other bearish stance at Underweight, with a US-listed target of $14 set in August.
Bernstein carries Market Perform at $18.
Goldman Sachs analyst Tina Hou cut her Hong Kong target to HK$69 from HK$77 after the second-quarter results while keeping a Buy rating.
Bank of America and Macquarie also rate the stock Buy, with targets implying between 25.6% and 70.4% upside from late-August levels.
UBS itself increased its XPeng equity holding by 27.0% during the second quarter to 5.58 million American depositary shares, valued at about $73.9 million at quarter-end — a position that has nonetheless shrunk 25% from its Q1 2025 level.
